225 related articles for article (PubMed ID: 35790883)
1. A comprehensive study of alternative splicing in malignant pleural mesothelioma identifies potential therapeutic targets in a new cluster with poor survival.
Shao MM; Qiao X; Chen QY; Yi FS
Thorac Cancer; 2022 Aug; 13(16):2318-2330. PubMed ID: 35790883
[TBL] [Abstract][Full Text] [Related]
2. Co-occurring Mutations of Tumor Suppressor Genes,
Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
[No Abstract] [Full Text] [Related]
3. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
[TBL] [Abstract][Full Text] [Related]
4. Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma.
Greillier L; Tounsi A; Berenguer-Daizé C; Dussault N; Delfino C; Benyahia Z; Cayol M; Mabrouk K; Garcia S; Martin PM; Barlesi F; Ouafik L
J Thorac Oncol; 2016 Jan; 11(1):94-107. PubMed ID: 26762744
[TBL] [Abstract][Full Text] [Related]
5. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
Arimura K; Hiroshima K; Nagashima Y; Nakazawa T; Ogihara A; Orimo M; Sato Y; Katsura H; Kanzaki M; Kondo M; Tagaya E
BMC Cancer; 2023 Dec; 23(1):1206. PubMed ID: 38062416
[TBL] [Abstract][Full Text] [Related]
6. An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.
Linton A; Cheng YY; Griggs K; Schedlich L; Kirschner MB; Gattani S; Srikaran S; Chuan-Hao Kao S; McCaughan BC; Klebe S; van Zandwijk N; Reid G
Br J Cancer; 2014 Jan; 110(2):510-9. PubMed ID: 24327015
[TBL] [Abstract][Full Text] [Related]
7. [Expression and prognostic significance of KAP1 gene in malignant pleural mesothelioma].
Mei W; Wang XM; Liu RA; Xiong W; Zhang YP
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2024 Apr; 42(4):258-267. PubMed ID: 38677988
[No Abstract] [Full Text] [Related]
8. Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth
Laszlo V; Valko Z; Kovacs I; Ozsvar J; Hoda MA; Klikovits T; Lakatos D; Czirok A; Garay T; Stiglbauer A; Helbich TH; Gröger M; Tovari J; Klepetko W; Pirker C; Grusch M; Berger W; Hilberg F; Hegedus B; Dome B
Clin Cancer Res; 2018 Aug; 24(15):3729-3740. PubMed ID: 29724868
[No Abstract] [Full Text] [Related]
9. POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma.
Shimizu D; Ishibashi M; Yamada T; Toda Y; Hosogi S; Ashihara E
Cancer Genomics Proteomics; 2024; 21(2):158-165. PubMed ID: 38423601
[TBL] [Abstract][Full Text] [Related]
10. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications.
Blum Y; Meiller C; Quetel L; Elarouci N; Ayadi M; Tashtanbaeva D; Armenoult L; Montagne F; Tranchant R; Renier A; de Koning L; Copin MC; Hofman P; Hofman V; Porte H; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; de Reyniès A; Jean D
Nat Commun; 2019 Mar; 10(1):1333. PubMed ID: 30902996
[TBL] [Abstract][Full Text] [Related]
11. Prognostic risk assessment model for alternative splicing events and splicing factors in malignant pleural mesothelioma.
Jiang Y; Zhang C; Chen Y; Zhao S; He Y; He J
Cancer Med; 2023 Feb; 12(4):4895-4906. PubMed ID: 36031798
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
[TBL] [Abstract][Full Text] [Related]
13. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.
Suraokar MB; Nunez MI; Diao L; Chow CW; Kim D; Behrens C; Lin H; Lee S; Raso G; Moran C; Rice D; Mehran R; Lee JJ; Pass HI; Wang J; Momin AA; James BP; Corvalan A; Coombes K; Tsao A; Wistuba II
Ann Oncol; 2014 Jun; 25(6):1184-92. PubMed ID: 24669013
[TBL] [Abstract][Full Text] [Related]
14. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
[No Abstract] [Full Text] [Related]
15. KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.
Cheng YY; Wright CM; Kirschner MB; Williams M; Sarun KH; Sytnyk V; Leshchynska I; Edelman JJ; Vallely MP; McCaughan BC; Klebe S; van Zandwijk N; Lin RC; Reid G
Mol Cancer; 2016 Jun; 15(1):44. PubMed ID: 27245839
[TBL] [Abstract][Full Text] [Related]
16. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
Ramírez-Salazar EG; Salinas-Silva LC; Vázquez-Manríquez ME; Gayosso-Gómez LV; Negrete-Garcia MC; Ramírez-Rodriguez SL; Chávez R; Zenteno E; Santillán P; Kelly-García J; Ortiz-Quintero B
Exp Mol Pathol; 2014 Dec; 97(3):375-85. PubMed ID: 25236577
[TBL] [Abstract][Full Text] [Related]
17. Differentially expressed alternatively spliced genes in malignant pleural mesothelioma identified using massively parallel transcriptome sequencing.
Dong L; Jensen RV; De Rienzo A; Gordon GJ; Xu Y; Sugarbaker DJ; Bueno R
BMC Med Genet; 2009 Dec; 10():149. PubMed ID: 20043850
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.
Shukuya T; Oyanagi J; Serizawa M; Watanabe M; Yamamoto N; Koh Y
Anticancer Res; 2020 Apr; 40(4):1867-1874. PubMed ID: 32234874
[TBL] [Abstract][Full Text] [Related]
19. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
Rao M; Atay SM; Shukla V; Hong Y; Upham T; Ripley RT; Hong JA; Zhang M; Reardon E; Fetsch P; Miettinen M; Li X; Peer CJ; Sissung T; Figg WD; De Rienzo A; Bueno R; Schrump DS
Clin Cancer Res; 2016 Mar; 22(5):1197-210. PubMed ID: 26459178
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.
Laszlo V; Hoda MA; Garay T; Pirker C; Ghanim B; Klikovits T; Dong YW; Rozsas A; Kenessey I; Szirtes I; Grusch M; Jakopovic M; Samarzija M; Brcic L; Kern I; Rozman A; Popper H; Zöchbauer-Müller S; Heller G; Altenberger C; Ziegler B; Klepetko W; Berger W; Dome B; Hegedus B
J Pathol; 2015 Oct; 237(2):203-14. PubMed ID: 26011651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]